Rothschild Investment LLC’s BridgeBio Pharma BBIO Stock Holding History

Rothschild Investment LLC’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16K	Sell	215 -56	-21%	-$3.92K	﹤0.01%	1643
2026 Q1	$20.1K	Buy	271 +22	+9%	+$1.59K	﹤0.01%	1411
2025 Q4	$19K	Buy	249 +9	+4%	+$591	﹤0.01%	1337
2025 Q3	$12.5K	Sell	240 -60	-20%	-$2.93K	﹤0.01%	1366
2025 Q2	$13K	Buy	300 +50	+20%	+$1.82K	﹤0.01%	1142
2025 Q1	$8.64K	Buy	250 +85	+52%	+$2.87K	﹤0.01%	1211
2024 Q4	$4.53K	Buy	165 +20	+14%	+$517	﹤0.01%	1387
2024 Q3	$3.69K	Buy	145 +105	+263%	+$2.76K	﹤0.01%	1407
2024 Q2	$1.01K	Buy	40 +30	+300%	+$820	﹤0.01%	1649
2024 Q1	$309	Buy	+10	New	+$340	﹤0.01%	1547

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Rothschild Investment LLC's BBIO Position: Q2 2026 in Review

Rothschild Investment LLC reduced its BridgeBio Pharma (BBIO) stake by 21% in Q2 2026, selling an estimated $3.92K and leaving 215 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #1643.

Rothschild Investment LLC first reported a position in BBIO in Q1 2024 and has held it in 10 quarters since. The position peaked at $20.1K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Rothschild Investment LLC held 215 shares of BridgeBio Pharma worth $16K as of Q2 2026.
Rothschild Investment LLC sold 56 BridgeBio Pharma shares in Q2 2026, an estimated $3.92K.
BridgeBio Pharma made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #1643 holding.
Rothschild Investment LLC first reported a position in BridgeBio Pharma in Q1 2024 and has held it in 10 quarters since.
Rothschild Investment LLC's BridgeBio Pharma position peaked at $20.1K in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.